"The voice for cancer physicians and their patients in Massachusetts."

SACITUZUMAB GOVITECAN-HZIY (TRODELVY) IS NOW A CATEGORY 1 PREFERRED TREATMENT OPTION, AS EARLY AS 2L FOR mTNBC

10 Aug 2022 7:45 AM | Katy Monaco (Administrator)

NCCN GUIDELINES®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a Category 1 preferred treatment option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Read More

Learn more about TRODELVY.  Please click to see full Prescribing Information

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software